2019 issue 1

Back

Volume 35, issue 1

Review article

Cerebrolysin – mechanism of action and application in psychiatry and neurology

Katarzyna Bliźniewska-Kowalska1, Maria Łukasik1, Piotr Gałecki1
1. Klinika Psychiatrii Dorosłych Uniwersytetu Medycznego w Łodzi
Farmakoterapia w Psychiatrii i Neurologii 2019, 35 (1), 9–23
Date of publication: 20-03-2019
DOI: https://doi.org/10.33450/fpn.2019.03.002
Keywords: cerebrolysin, neuronal plasticity, neurogenesis, brain injuries

Abstract

Cerebrolysin is a medication, which has been used in psychiatry and neurology for over 50 years. The aim of this paper is to present the current state of knowledge on cerebrolysin. It is a non-lipid mixture of free L-amino acids and neuropeptides of low molecular weight that are purified via enzymatic proteolysis from brains of young pigs. It also contains magnesium, phosphorus, potassium and selenium. Cerebrolysin passes the blood-brain barrier. It was proved that it supports endogenous regeneration processes, mimics the behaviour of neurotrophic factors and modifies their level, affects the Sonic Hedgehog protein’s signalling pathway, protects from the pathological events and cascades which stem from an injury or a neurodegenerative disease, reduces amounts of free radicals as well as pro-apoptotic enzymes, modulates inflammatory response and also affects neuroplasticity and neurogenesis. Because of these characteristics, cerebrolysin is used in treatment of patients suffering from strokes, traumatic brain injuries, patients with cognitive disorders, including Alzheimer’s dementia and vascular dementia. The standard route of administration is via injections; however, some research was conducted on oral administration as well. The commonly reported adverse effects of cerebrolysin are transient and of mild severity. Results of research on the effectiveness and safety of cerebrolysin seem to be encouraging. They confirm high safety level and theoretical legitimacy of its use. The treatment of patients with organic, metabolic and neurodegenerative syndromes is difficult and often ineffective. Therefore, every available method of treatment needs to be taken under consideration.

Address for correspondence:
Katarzyna Bliźniewska-Kowalska
Klinika Psychiatrii Dorosłych Uniwersytetu Medycznego w Łodzi
ul. Aleksandrowska 159, 91-229 Łódź, Poland
email: kblizniewska@gmail.com